TW202339753A - 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物 - Google Patents

用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物 Download PDF

Info

Publication number
TW202339753A
TW202339753A TW112103190A TW112103190A TW202339753A TW 202339753 A TW202339753 A TW 202339753A TW 112103190 A TW112103190 A TW 112103190A TW 112103190 A TW112103190 A TW 112103190A TW 202339753 A TW202339753 A TW 202339753A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
combination
cancer
administration
administered
Prior art date
Application number
TW112103190A
Other languages
English (en)
Chinese (zh)
Inventor
李原植
河慶珠
魯珢振
李銘宰
洪民主
崔成延
金正恩
齊銀桂
劉雲蘭
林鍾河
Original Assignee
南韓商愛迪恩斯股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南韓商愛迪恩斯股份有限公司 filed Critical 南韓商愛迪恩斯股份有限公司
Publication of TW202339753A publication Critical patent/TW202339753A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW112103190A 2022-01-25 2023-01-30 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物 TW202339753A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263302834P 2022-01-25 2022-01-25
US63/302,834 2022-01-25

Publications (1)

Publication Number Publication Date
TW202339753A true TW202339753A (zh) 2023-10-16

Family

ID=87470837

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112103190A TW202339753A (zh) 2022-01-25 2023-01-30 用於與抗癌藥物共同投與之包含酞嗪酮衍生物之醫藥組合物

Country Status (14)

Country Link
US (1) US20250120970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469051A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505381A (cg-RX-API-DMAC7.html)
KR (1) KR20240138069A (cg-RX-API-DMAC7.html)
CN (1) CN118613264A (cg-RX-API-DMAC7.html)
AU (1) AU2023210923A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249330A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002218A1 (cg-RX-API-DMAC7.html)
IL (1) IL314334A (cg-RX-API-DMAC7.html)
JO (1) JOP20240162A1 (cg-RX-API-DMAC7.html)
MA (1) MA66598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009168A (cg-RX-API-DMAC7.html)
TW (1) TW202339753A (cg-RX-API-DMAC7.html)
WO (1) WO2023144626A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
WO2021214502A1 (en) * 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) * 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형

Also Published As

Publication number Publication date
CA3249330A1 (en) 2023-08-03
MX2024009168A (es) 2024-08-09
JP2025505381A (ja) 2025-02-26
EP4469051A1 (en) 2024-12-04
KR20240138069A (ko) 2024-09-20
CN118613264A (zh) 2024-09-06
MA66598A1 (fr) 2024-11-29
IL314334A (en) 2024-09-01
CL2024002218A1 (es) 2024-12-20
WO2023144626A1 (en) 2023-08-03
EP4469051A4 (en) 2025-12-17
AU2023210923A1 (en) 2024-07-25
US20250120970A1 (en) 2025-04-17
JOP20240162A1 (ar) 2024-07-23

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
US8507555B2 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
EP3638232B1 (en) Tinostamustine for use in treating sarcoma
AU2015314753A1 (en) Human dosing of phosphatase inhibitor
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20120053211A1 (en) Treatment of pancreatic cancer
KR100858946B1 (ko) 초기 유방암을 가진 폐경후 여성의 치료를 위한아나스트로졸의 용도
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
TW201600086A (zh) 用於治療三陰性乳癌之維利帕尼(veliparib)與卡鉑之組合
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
HK40111558A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
JP7762224B2 (ja) 線維化症の予防または治療用薬学的組成物
RU2784869C1 (ru) Чиаураниб для лечения мелкоклеточного рака легкого
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるpi3キナーゼ阻害剤とパクリタキセルの組合せ
US20200299355A1 (en) Methods for diagnosing and treating diseases based on modulating drug efflux by binding to cryptic region of cd44
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、P-gp阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
JP2019108385A (ja) がん治療
US20150209364A1 (en) Method for treating epidermoid carcinoma
HK1231735B (en) Methods and uses of quinoline derivatives in the treatment of thyroid cancer and pharmaceutical compositions for treatment of same
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2010004337A1 (en) Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed